Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2-SADA:177Lu-DOTA in GD2-expressing Solid Tumors
NCT05130255Phase 1Terminated
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Nov 2022
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of GD2-SADA and lutetium (177Lu) oxodotreotide in small cell lung cancer (SCLC), neuroblastoma, sarcoma and 1 more (6 cohorts), sponsored by Y-mAbs Therapeutics, Inc. Primary endpoint: Dose Limiting Toxicity at 6 weeks. Started Nov 2022; status: terminated.
02
Drugs
GD2-SADAlutetium (177Lu) oxodotreotide
03
Conditions
small cell lung cancer (SCLC)neuroblastomasarcomamelanoma
Beyond the preview
Go deeper on NCT05130255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130255.